14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Monday, 22nd Apr 2024 ADAP stock ended at $1.01. This is 3.41% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 13.34% from a day low at $0.95 to a day high of $1.08.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Apr 22, 2022 $1.92 $1.96 $1.85 $1.89 353 900
Apr 21, 2022 $2.00 $2.06 $1.88 $1.91 766 400
Apr 20, 2022 $1.97 $2.32 $1.93 $2.01 1 759 700
Apr 19, 2022 $1.81 $1.96 $1.81 $1.92 299 200
Apr 18, 2022 $1.92 $1.92 $1.83 $1.84 449 700
Apr 14, 2022 $1.96 $1.97 $1.88 $1.91 575 126
Apr 13, 2022 $1.77 $1.95 $1.77 $1.95 1 187 842
Apr 12, 2022 $1.88 $1.90 $1.78 $1.79 541 136
Apr 11, 2022 $2.13 $2.13 $1.84 $1.86 1 102 930
Apr 08, 2022 $2.25 $2.34 $2.15 $2.18 545 200
Apr 07, 2022 $2.25 $2.34 $2.22 $2.24 503 000
Apr 06, 2022 $2.18 $2.30 $2.10 $2.28 690 200
Apr 05, 2022 $2.20 $2.24 $2.17 $2.17 438 600
Apr 04, 2022 $2.12 $2.26 $2.12 $2.23 506 100
Apr 01, 2022 $2.07 $2.15 $2.01 $2.12 355 751
Mar 31, 2022 $2.07 $2.07 $2.02 $2.06 279 824
Mar 30, 2022 $2.14 $2.16 $2.03 $2.07 218 210
Mar 29, 2022 $2.07 $2.18 $2.05 $2.13 316 400
Mar 28, 2022 $2.08 $2.13 $2.01 $2.05 460 500
Mar 25, 2022 $2.22 $2.22 $2.06 $2.10 455 600
Mar 24, 2022 $2.17 $2.24 $2.12 $2.19 463 800
Mar 23, 2022 $2.24 $2.26 $2.15 $2.16 510 900
Mar 22, 2022 $2.13 $2.26 $2.08 $2.25 586 696
Mar 21, 2022 $2.18 $2.19 $2.10 $2.13 1 012 195
Mar 18, 2022 $2.06 $2.24 $2.04 $2.18 1 332 013
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT